A Study of Lerociclib in Participants With Advanced Breast Cancer

Stopped early · Phase 2

Conditions studied: Advanced Breast Cancer

In brief

This is a multicenter, single-arm, open-label study to evaluate the safety and efficacy of lerociclib in combination with standard endocrine therapy in female or male participants with HR+/HER2- MBC. The study population will consist of either newly diagnosed, treatment naïve participants with HR+/HER2- MBC (1L population) and participants with HR+/HER2- MBC who have already progressed on first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population). All premenopausal or perimenopausal female participants, and all male participants, must be receiving goserelin for at least 28 days prior to entering the study and will remain on goserelin throughout the study, in accordance with the prescribing information and according to the study site's standard practice.

Key facts

Study ID

NCT05085002

Run by

EQRx, Inc.

People needed

100

Starts

2021-12-21

Expected to finish

2023-11-29

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
• Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer.
• Advanced (locoregionally recurrent not amenable to curative therapy, eg, surgery and/or radiotherapy, or metastatic) breast cancer
• Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
• Adequate bone marrow and organ function
• Female that is not pregnant and agrees to contraceptive use that is consistent with local regulations regarding the methods of contraception to be used during the study
• Males agree to use a highly effective method of contraception and will refrain from donating sperm from the first dose of any study intervention
• Participant is capable of giving signed informed consent

You may not qualify if…

• Symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the Investigator's best judgment.
• Peritoneal carcinomatosis.
• Inflammatory breast cancer at screening.
• Participant with central nervous system (CNS) involvement unless they are at least 4 weeks from prior therapy completion to starting the study treatment and have stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases.
• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
• Has a history of prolonged QT syndrome or Torsades de Pointes
• Has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy) or any CDK4/6 inhibitor.
• Has received prior treatment with fulvestrant.
• Use of systemic estrogens
• Participant is currently receiving any of the following substances and cannot be discontinued 14 days prior to start the treatment:
• Known strong or moderate CYP3A inducers or strong inhibition of CYP3A
• Substances that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
• Echocardiogram done within the past 12 months with ejection fraction of ≤ 45% or documented history of congestive heart failure with reduced ejection fraction.
• Evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or oral temperature > 38°C at screening
• Interstitial pneumonia or severe impairment of lung function

Where it is running

• Cancer Specialists of North Florida — Jacksonville, Florida, United States
• Nebraska Cancer Specialists — Omaha, Nebraska, United States
• Oregon Oncology Specialists — Salem, Oregon, United States
• Cancer Care Associates of York, Inc. — York, Pennsylvania, United States
• Tranquil Clinical Research — Webster, Texas, United States
• Northwest Medical Specialties PLLC — Tacoma, Washington, United States
• UZA — Edegem, Belgium
• Ziekenhuizen K.U.Leuven, Campus gasthuisberg — Leuven, Belgium
• CHA Libramont — Libramont, Belgium
• Clinique Saint-Pierre asbl — Ottignies, Belgium
• vzw Verenigde Ziekenhuizen van Waas en Durme - VITAZ — Sint-Niklaas, Belgium
• LTD "Brothers" — Batumi, Georgia
• ARENSIA Exploratory Medicine LLC — Tbilisi, Georgia
• Ltd Israeli-Georgian Medical Research Clinic Helsicore — Tbilisi, Georgia
• LTD "Health House" — Tbilisi, Georgia
• Ltd "Multiprofile Clinic Consilium Medulla " — Tbilisi, Georgia
• Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" — Meldola, Italy
• PanAmerican Clinical Research Guadalajara — Guadalajara, Jalisco, Mexico
• PanAmerican Clinical Research Cuernavaca — Cuernavaca, Mexico
• PanAmerican Clinical Research, Queretaro — Querétaro, Mexico
• IMSP Institutul Oncologic, Arsenia Exploratory Medicine — Chisinau, Moldova

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.